I wish Evolus was cleaner comp when looking at when they originally launched to where they are now. It’d be a nice barometer for Daxxify. But since they essentially had to shut down with the litigation with Abbvie/Medytox and then had to re-launch later, the comp makes it trickier. Regardless, I’m not really expecting much strength in Q3 for RVNC/Daxxify. Probably a little over Q2…..roughly $25MM. But I think Q4 will be 35-40% over Q3 $34-$35MM) and I’ll be looking for any hint or language they give regarding increase in demand with new pricing. And commentary on margins.
Is there a viable market for CD? It is realistic to expect peak sales of $350M? How long do you think it will take? I I have been adding over the last week. Pretty drastic drop, from $37 to $6. People expecting the company to go bankrupt. We'll see what the next few quarters bring.
News 
Market Data 
Discover 
